Haemonetics (HAE) Q4 2026 Earnings Transcript

Haemonetics reported Q4 revenue of $346 million, up 5% reported and 9% organic ex-CSL, with adjusted EPS of $1.29 and full-year adjusted EPS up 9% to $4.96. Full-year adjusted gross margin expanded 280 bps to 60.3% and operating margin rose 140 bps to 25.4%, while free cash flow totaled $210 million and the company returned $175 million via buybacks. FY2027 guidance calls for 4% to 7% reported revenue growth, 50 to 100 bps of operating margin expansion, and about 80% free cash flow conversion, supported by Persona PLUS, MVP XL, and Vivasure integration.

Analysis

HAE is finally moving from a self-help story to a cleaner operating compounding story, and the market should care less about the headline guide than about the mix of growth drivers underneath it. The important second-order effect is that the company is not just repairing revenue; it is increasing the share of revenue coming from recurring, consumable, and upgrade-driven streams, which should make gross margin and cash conversion less volatile than the reported top-line range implies. That matters because the stock has likely traded at a structural discount for execution noise, not because the core economics are weak.

The bigger setup is that several pressures that previously masked underlying quality are fading at once: portfolio transition drag is gone, IVT looks like it is moving from contraction to stabilization, and plasma now has a new upgrade cycle that can support pricing even if collection volumes stay only modestly positive. The market may be underestimating how much operating leverage emerges when three growth engines reaccelerate in parallel while the company is already at low net leverage and still buying back stock. That combination usually drives multiple expansion before the Street fully ups its forward estimates.

The key risk is that guidance still bakes in a lot of launch optimism without revenue from the newest products, so the next 2 quarters become a validation window rather than a victory lap. If FDA timing slips, if Persona PLUS adoption is slower than implied, or if tariff inflation proves stickier, the earnings trajectory can look more linear than explosive. In other words, the setup is good, but the asymmetry is most attractive if management keeps converting innovation into measured pricing power by late 2026 rather than relying on volume alone.

Key Decisions for Investors

• Long HAE into the next 1-2 quarters on the thesis that the market will re-rate the stock as a cleaner compounder; target a 12-18 month horizon with upside from multiple expansion if IVT and plasma both inflect as guided.
• Sell downside protection via put spreads on HAE rather than outright chasing upside; the near-term risk is execution/timing, but the balance sheet and buyback support make a crash scenario less likely over 6-9 months.
• Pair trade: long HAE / short a more mature medical device name with slower organic growth and less recurring mix, to isolate self-help and launch optionality rather than beta.
• Monitor FDA timing on PerQseal and adoption velocity for Persona PLUS over the next 2 earnings prints; if either slips materially, reduce exposure because the 2027 guide likely embeds too much confidence in launch sequencing.
• If HAE rallies sharply on the print, consider trimming into strength and waiting for a post-guidance consolidation; the stock likely needs proof of pricing realization before the street rewards the full innovation stack.